anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SIGNIFICANCE: Imposing a time limit on the Farnsworth D15 test may prevent patients from compromising the test.
PURPOSE: This study aimed to investigate the effect of test time on the Farnsworth D15 color vision test in unpracticed and practiced subjects and determine an optimal test time.
METHODS: Twenty-one subjects (mean/standard deviation age, 33.1/9.3 years) with a range of congenital color vision deficiency participated in the study. Pseudoisochromatic plate screening, Farnsworth D15, and anomaloscope testing were performed for classification purposes. At each of 2 visits, 10 trials of the Farnsworth D15 were performed with a range in test times from 30 seconds to 10 minutes. Between visits, subjects practiced the test. Major crossovers were used as the outcome measure. A repeated-measures analysis of variance compared the scores across trials. Post hoc Dunnett's testing analyzed the pairwise data.
RESULTS: Although no significant difference in the mean number of major crossovers was found across the 10 trials for the first visit ( F (9, 180) = 1.30, p=0.24), a significant difference was found for the second visit ( F (9, 180) = 4.77, p<0.001). The range of mean number of major crossovers for the second visit was 1.71 to 5.1, with the 30-second trial resulting in the largest number of major crossovers and the longest trial resulting in the smallest number of major crossovers. Analysis showed that a 2-minute time limit resulted in a Farnsworth D15 outcome that would be expected based on the anomaloscope for a majority of subjects.
CONCLUSIONS: In this study, test time was found to affect performance in practiced subjects but not in unpracticed subjects. Based on this study, we recommend enforcing a time limit of 2 minutes to discourage those who try to pass the Farnsworth D15 through practice. Additional measures, such as recording patient behavior, can also be taken.
UNLABELLED: Time-restricted eating (TRE) is a circadian rhythm-based intermittent fasting intervention that has been used to treat obesity. However, the efficacy and safety of TRE for fat loss have not been comprehensively examined and the influences of TRE characteristics on such effects are unknown. This systematic review and meta-analysis comprehensively characterized the efficacy and safety of TRE for fat loss in adults with overweight and obese, and it explored the influence of TRE characteristics on this effect.
METHODS: A search strategy based on the PICOS principle was used to find relevant publications in seven databases. The outcomes were body composition, anthropometric indicators, and blood lipid metrics. Twenty publications (20 studies) with 1288 participants, covering the period from 2020 to 2024, were included.
RESULTS: Compared to the control group, TRE safely and significantly reduced body fat percentage, fat mass, lean mass, body mass, BMI, and waist circumference (MDpooled = -2.14 cm, 95% CI = -2.88~-1.40, p < 0.001), and increased low-density lipoprotein (LDL) (MDpooled = 2.70, 95% CI = 0.17~5.22, p = 0.037), but it did not alter the total cholesterol, high-density lipoprotein, and triglycerides (MDpooled = -1.09~1.20 mg/dL, 95% CI -4.31~5.47, p > 0.05). Subgroup analyses showed that TRE only or TRE-caloric restriction with an eating window of 6 to 8 h may be appropriate for losing body fat and overall weight.
CONCLUSIONS: This work provides moderate to high evidence that TRE is a promising dietary strategy for fat loss. Although it may potentially reduce lean mass and increase LDL, these effects do not pose significant safety concerns. This trial was registered with PROSPERO as CRD42023406329.
The present invention relates to lipid compositions derived from insects. The intrinsic chemical/physical properties of insect derived lipids limit the possibilities for widespread and large-scale use. An enzymatic process for the partial hydrolysis and transesterification of insect extracted lipids is provided. The process alters the ratio of triglyceride (TAG), diglycerides (DAG), monoglycerides (MAG) and free fatty acids (FFA) of the crude insect lipid and also results in the transesterification of fatty acids on glyceride backbone yielding a lipid composition that combines an increased dispersibility in water, a more favourable hardness profile (as a function of temperature) and a melting point slightly above ambient temperature. The compositions of the invention further have good nutritive properties as well as some interesting functional properties, e.g. anti-microbial effects. The invention relates to these enzyme-modified lipid compositions, to the methods for producing them, as well as to their uses as an ingredient in an alimentary product.
A randomized controlled clinical trial with three parallel groups, will be set up and reported according to the revised Consolidated Standards of Reporting Trials statement. The study will be conducted on 51 children with 51 molars aged between 4 and 7 years with a lower primary molar indicated for crown restoration. The children will be selected from the Pediatric Dental Clinic, Faculty of Dentistry, Mansoura University. They will be randomly divided into three equal groups (17 molars/each). Sequence generation and concealment will be done by a biostatistician who is not involved in the study. Group I (control group) will include stainless steel crowns, group II (study group) will include Zirconia crowns, group III (study group) will include BioFlx crowns. After obtaining the written consent form from the parents or guardians, the children will be randomly enrolled, and teeth will be assigned to the groups to receive the selected crowns. Clinical evaluation will be done concerning crown retention, color stability, secondary caries, periodontal changes, and wear of the opposing natural enamel. All crowns will be evaluated at the 3rd, 6th, 12th, and 18th months.
FIELD: cosmetics. SUBSTANCE: invention relates to cosmetic composition designated for oxidative staining keratin fibers. The composition comprises the following components in a carrier corresponding to keratin fibers staining: (a) enzyme of laccase type; (b) thickening polymer taken among group consisting of: (i) non-ionic amphiphilic polymers including aliphatic chain and hydrophilic link; (ii) anionic amphiphilic polymers including hydrophilic link and link with aliphatic chain; (iii) cross-linked homopolymers of acrylic acid; (iv) cross-linked homopolymers of 2-acrylamido-2-methylpropane sulfoacid and partially or fully neutralized cross-linked copolymers of 2-acrylamido-2-methylpropane sulfoacid with acrylamide; (v) homopolymers of ammonium acrylate or copolymers of ammonium acrylate with acrylamide; (vi) homopolymers of dimethylaminoethyl acrylate quaternized with methyl chloride or copolymers of dimethylaminoethyl methacrylate quaternized with methyl chloride with acrylamide; (vii) non-ionic guare resins; (viii) scleroglucane resins (biopolysaccharide of bacterial origin); (ix) gums originating from vegetable exudates, for example, gum arabic and tragacanth gum; (c) dye fixing in oxidation. Invention relates also to method for staining where this composition is used. Invention provides uniform, chromatic and intense hair staining. EFFECT: valuable properties of composition. 33 cl
Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
OBJECTIVE: This study aims to investigate the expression levels of Nerve Growth Factor (NGF), the precursor form of NGF (proNGF), and p75 neurotrophin receptor (p75NTR) in lung injury induced by cerebral Ischemia-Reperfusion (I/R) in both young and elderly rats.
METHODS: Male Sprague-Dawley rats, categorized as young (3-months-old) and elderly (16-months-old), were divided into four experimental groups: Young Sham, Young I/R, Elderly Sham, and Elderly I/R. Each group underwent either sham surgery or ischemia-reperfusion treatment. Following 24 h post-procedure, the severity of cerebral ischemia was assessed using the Zea Longa 5-point scoring system, and lung tissue pathological changes were examined using Hematoxylin and Eosin (HE) staining. Western blot analysis was utilized to measure the expression levels of NGF, proNGF, and p75NTR proteins in lung tissue.
RESULTS: Both young and elderly I/R groups exhibited lung tissue congestion and edema compared to their respective sham groups, with a significant increase in pathological scores (p < 0.05). Furthermore, the elderly I/R group demonstrated a significantly higher pathological score compared to the young I/R group (p < 0.05). Western blot analysis revealed that compared to the young sham group, the expression of NGF in the lung tissue of elderly sham rats decreased (p < 0.05), while proNGF and p75NTR increased (p < 0.05). Additionally, compared to the sham group, the levels of NGF, proNGF, and p75NTR in lung tissue were elevated in both young and elderly I/R groups of rats (p < 0.05). Moreover, the expression of proNGF and p75NTR in lung tissue was higher in the elderly I/R group than in the young I/R group (p < 0.05).
CONCLUSION: Cerebral ischemia-reperfusion-induced lung injury was associated with increased expression of proNGF and p75NTR, as well as decreased NGF expression in lung tissue. These alterations in NGF, proNGF, and p75NTR may contribute to the susceptibility to age-related lung injury.
Tofacitinib 5mg twice daily orally. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD.
The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
It is an observational study. The aim of the observational study is to compare static, kinematic and kinetic parameters with normal gait parameters in cases with Idiopathic toe walking (ITW) and Diparetic Cerebral Palsy (DCP) who have Gross Motor Function Classification System 1 level with the 3D Gait Analysis method, and to enable the early diagnosis of DCP and ITW. Male and female cases aged between 3-18 years will be included. This study will be carried out at Acıbadem Altunizade Hospital. 51 cases will be included in our study. These cases will be divided into three groups. The first group will consist of patients diagnosed with idioaptic toe walking (n:17), the second group will be composed of diparetic cerebral palsy (n:15) with independent ambulation, and the third group will be the control group (n:19). First, the demographic information of the cases will be recorded. With 3D walking analysis, kinetic, kinematic and static data will be collected. The analysis of the obtained data will be done with Polygon Software (Vicon, Oxford, UK). Evaluated kinetic, kinematic and static parameters will be compared between three groups.

Is the lower extremity compensation of children with diparetic cerebral palsy who can walk independently more than children with idiopathic toe walking?
The control group will not participate in the newsletter creation for the 7-week study period. These students will engage in the after-school programs at the Center, some of which may be literacy-based, but not the prescriptive model that is being followed by the researchers.
Deep vein thrombosis (DVT) of the lower extremities is one of the most common peripheral vascular diseases, with significant complications and sequelae. Metabolomics aims to identify small molecules in biological samples. It can serve as a promising method for screening compounds that can be used for early disease detection, diagnosis, treatment response prediction, and prognosis. In addition, high-throughput metabolomics screening can yield significant insights into the pathophysiological pathways of DVT. Currently, the metabolomic profiles of DVT have yielded inconsistent expression patterns. This article examines the recent advancements in metabolomic studies of DVT and analyzes the factors that may influence the results.
OBJECTIVES: To investigate the clinical characteristics and risk factors of delayed bleeding after intestinal polypectomy in children, and to provide a theoretical basis for clinical surgical intervention of intestinal polyps.
METHODS: A retrospective analysis was conducted on the clinical data of 2 456 children with intestinal polyps who underwent endoscopic high-frequency electrocoagulation loop resection in the Endoscopy Center of Children's Hospital Affiliated to Zhengzhou University from January 2014 to December 2021. According to the presence or absence of delayed bleeding after surgery, they were divided into bleeding group with 79 children and non-bleeding group with 2 377 children. A multivariate logistic regression analysis was used to investigate the risk factors for delayed bleeding. The receiver operating characteristic (ROC) curve was used to investigate the value of various indicators in predicting delayed bleeding.
RESULTS: Of all 2 456 children, 79 (3.22%) experienced delayed bleeding, among whom 5 children with severe delayed bleeding underwent emergency colonoscopy for hemostasis and 74 received conservative treatment, and successful hemostasis was achieved for all children. There were significant differences between the bleeding and non-bleeding groups in age, body mass index, constipation rate, location of lesion, time of endoscopic procedure, resection method (P<0.05). Children with a diameter of polyps of 6-10 mm and >20 mm were more likely to develop delayed bleeding after resection (P<0.05). The multivariate logistic regression analysis showed that endoscopic operation time, polyp diameter, and resection method were significantly associated with delayed bleeding (P<0.05). The ROC curve analysis showed that the endoscopic operation time, polyp diameter, and resection method had a good value in predicting delayed bleeding after intestinal polypectomy, with an area under the ROC curve of 0.706, 0.688, and 0.627, respectively.
CONCLUSIONS: Endoscopic high-frequency electrocoagulation loop resection has a lower incidence of delayed bleeding in children with intestinal polyps, and the endoscopic operation time, polyp diameter, and resection method are closely associated with the occurrence of postoperative delayed bleeding.
Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
Methadone hydrochloride tablets for oral suspension, USP contain methadone, an opioid agonist, available as 40 mg dispersible tablets for oral administration. Methadone hydrochloride, USP is chemically described as 6-(dimethylamino)-4,4-diphenyl-3-heptanone hydrochloride. Methadone hydrochloride, USP is a white, essentially odorless, bitter-tasting crystalline powder. It is very soluble in water, soluble in isopropanol and in chloroform, and practically insoluble in ether and in glycerine. It is present in methadone hydrochloride tablets for oral suspension as the racemic mixture. Methadone hydrochloride, USP has a melting point of 235°C, a pKa of 8.25 in water at 20°C, a solution (1 part per 100) pH between 4.5 and 6.5, a partition coefficient of 117 at pH 7.4 in octanol/water and a molecular weight of 345.91. Its molecular formula is C21H27NO•HCl and its structural formula is:

Each methadone hydrochloride tablets for oral suspension, USP contain 40 mg of methadone hydrochloride, USP and the following inactive ingredients: colloidal silicon dioxide, corn starch, magnesium stearate, and microcrystalline cellulose.

Methadone hydrochloride tablets for oral suspension, USP are cross-scored, allowing for flexible dosage adjustment. Each tablet may be broken or cut in half to yield two 20 mg doses, or in quarters to yield four 10 mg doses.

Methadone hydrochloride tablets for oral suspension, USP are for oral administration following dispersion in a liquid.

Methadone hydrochloride tablets for oral suspension, USP contain insoluble excipients and must not be injected.
The invention discloses a lovastatin dispersing tablet for treating cardiovascular and cerebrovascular disease and a preparation method thereof. The lovastatin dispersing tablet with 5%-35% of weight percentage is taken as a main ingredient. Accessories contain a disintegrant, a loading agent, a wetting agent and a lubricant. A wetting method is used for pelleting and tabletting. The disintegrant can be internally added, externally added or internally and externally added. Compared with other dosage forms, the invention has the advantages of good dispersed state, short disintegration time, fast drug dissolution, low productions cost, and being convenient to take, carry, transport and store without needing special devices, etc.
During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
The novel invention provides for a system and a method to motivate care providers to ensure (a) compliance for a prescribed medical protocol for maintaining good health, and (b) collectively work together for speedy recovery of patients. The disclosed method and system help the care providers and care partner network to follow the prescribed medical protocols. The care providers are given the task of improving the health of patients. For the efforts, the care providers are rewarded with reward points based on improved health condition of patients. The rewards are recorded in the database as reward points. The reward points are converted into normalized points. These normalized points are credited into the account of the care providers as a reward for compliance with the treatment protocols.
In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m\^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m\^2 or 100 mg/m\^2) via IV infusion either in Q2W or Q3W + cyclophosphamide (C) 600 mg/m\^2 via IV infusion either in Q2W or Q3W for 4 cycles (Treatment 2). At no more than 6 weeks after last cycle of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
PURPOSE: A polysaccharide fraction is provided to enhance activity of a complements system and immunity in a normal mouse and an immunosuppressed mouse, and to effectively manufacture a food composition and a pharmaceutical product for enhancing immunity. CONSTITUTION: A persimmon leaf-derived polysaccharide fraction 70-90 wt% of neutral sugar and 10-30 wt% of uronic acid. Uronic acid is selected from the group consisting of galacturonic acid and glucuronic acid. The neutral sugar contains rhamnose, fucose, arabinose, xylose, mannose, galactose, and glucose. A food composition for enhancing immunity contains the polysaccharide fraction as an active ingredient. A method for preparing the polysaccharide fraction comprises a step of treating persimmon powder with pectinase.
PURPOSE: Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT.
MATERIALS AND METHODS: The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT.
RESULTS: Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976).
CONCLUSION: The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.
This a prospective, randomized, phase 2 clinical trial. We will enroll patients who underwent mpMRI of the prostate as part of their standard clinical care, have PI-RADS 4, or 5 lesion(s) on mpMRI, and are scheduled to undergo fusion guided prostate biopsy. Subjects that sign the consent form will be randomized to undergo DCFPyL PET/CT imaging or no PSMA PET imaging prior to the prostate biopsy. In the PSMA scan cohort, decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. In the no PSMA scan (control) group, the biopsy will be performed based on mpMRI findings. Each patient will undergo 12 core systematic biopsy as the standard of care. Two additional biopsies for each mpMRI and PSMA PET and overlap lesion will also performed.